Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Higgins

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Thorax|June 5, 2010
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDRonald Dahl, Kian Fan Chung, Roland Buhl, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 19, 2020
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutationEdward F McKone, Emily A DiMango, Sivagurunathan Sutharsan, et al.
Drugs|September 13, 2014
Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPDLorraine Murphy, Stephen Rennard, James Donohue, et al.
The Lancet. Respiratory Medicine|June 14, 2015
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trialRichard B Moss, Patrick A Flume, J Stuart Elborn, et al.
Respiratory Medicine|May 16, 2008
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparisonStephen Rennard, Theo Bantje, Stefano Centanni, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 29, 2022
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trialPatrick A Flume, R Scott Harris, Hildegarde Paz-Diaz, et al.
The Lancet. Respiratory Medicine|June 11, 2018
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyMargaret Rosenfeld, Claire E Wainwright, Mark Higgins, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2022
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for <i>F508del-CFTR</i>Jonathan H Rayment, Fadi Asfour, Margaret Rosenfeld, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 16, 2010
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trialMichael W Konstan, Patrick A Flume, Matthias Kappler, et al.
American Journal of Respiratory and Critical Care Medicine|May 14, 2010
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumJames F Donohue, Charles Fogarty, Jan Lötvall, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Thorax|June 5, 2010
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDRonald Dahl, Kian Fan Chung, Roland Buhl, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 19, 2020
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutationEdward F McKone, Emily A DiMango, Sivagurunathan Sutharsan, et al.
Drugs|September 13, 2014
Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPDLorraine Murphy, Stephen Rennard, James Donohue, et al.
The Lancet. Respiratory Medicine|June 14, 2015
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trialRichard B Moss, Patrick A Flume, J Stuart Elborn, et al.
Respiratory Medicine|May 16, 2008
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparisonStephen Rennard, Theo Bantje, Stefano Centanni, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 29, 2022
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trialPatrick A Flume, R Scott Harris, Hildegarde Paz-Diaz, et al.
The Lancet. Respiratory Medicine|June 11, 2018
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyMargaret Rosenfeld, Claire E Wainwright, Mark Higgins, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2022
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for <i>F508del-CFTR</i>Jonathan H Rayment, Fadi Asfour, Margaret Rosenfeld, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 16, 2010
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trialMichael W Konstan, Patrick A Flume, Matthias Kappler, et al.
American Journal of Respiratory and Critical Care Medicine|May 14, 2010
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumJames F Donohue, Charles Fogarty, Jan Lötvall, et al.
Pageof 6